AMRI gains new drug discovery tech through strategic alliance

AMRI gains new tech through strategic alliance

AMRI has entered an alliance through which the global contract research and manufacturing organization will gain access to "new avenues of drug discovery."

The alliance with Bruker Daltonics and HighRes Biosolutions looks to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. As part of this, AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions, which will be deployed at the company’s Drug Discovery Center in Buffalo, NY.

Additionally, Bruker Daltonics and HighRes Biosolutions will provide training and consulting to AMRI biologists.

The system, which combines Bruker’s MALDI mass spec with automation capabilities from HighRes Biosolutions, “opens up significant new avenues of drug discovery in diseases that need to be better understood such as complex neurodegenerative and inflammatory diseases,” Grant Carr, Ph.D., senior director, lead discovery for AMRI, told Ousourcing-Pharma.

Our scientists are especially excited to start working with the system,” he added.

Carr explained the MALDI technology has the potential to provide better experimental data for high throughput screening than older technologies, which he said rely on the addition of chemicals that can affect experiments.

However, previously, MALDI mass spec did not have the throughput to make it useful for hit discovery,” said Carr. “With the PharmaPulse system, throughputs greater than 50,000 samples screened per day can be achieved. AMRI will bring in its expertise in chemistry and biology to create assays that extend the utility of the system to complex cell-based assays for the identification of potential new drugs to meet a variety of unmet needs.”

The next steps involve installing the system and commencing protocol development to help AMRI customers advance their drug discovery projects.

(Feature image: iStock/JK1991)

Related News

AMRI will provide the consortium with a variety of drug discovery services (Image: iStock/Alexander Traksel)

AMRI to provide services for drug development consortium

The CRO now offers custom in vivo and in vitro genome editing through a licensing arrangement with the Broad Institute of MIT and Harvard. (Image: iStock/ktsimage)

CRISPR/Cas9 transforming research, says Charles River CSO

CRISPR-Cas9 is a gene editing tool that has implications in both disease treatment and drug discovery. (Image: iStock)

AMRI licenses CRISPR-Cas9 gene editing tech for drug discovery

The alliance between Charles River and Genentech dates back to 2005. (Image: iStock/AlexRaths)

Charles River extends drug discovery alliance with Genentech

Related Products

See more related products